Healthy adolescents aged 15–19 years are strongly recommended to receive MenACWY vaccine
Healthy adolescents aged 15–19 years are strongly recommended to receive a single dose of any MenACWY vaccine.
It is preferable for adolescents to receive either Menveo or Nimenrix, rather than Menactra. If Menveo and Nimenrix are unavailable, Menactra can be given.
Healthy adolescents may have received a dose of Menactra through one of the state and territory meningococcal vaccination programs. These adolescents do not need another dose of MenACWY vaccine.
Healthy adolescents who have received a dose of MenACWY vaccine in the past for other reasons — such as travel to a country where meningococcal disease is common — may or may not need a dose of MenACWY vaccine when they turn 15 years of age. The clinical need for a dose of MenACWY vaccine in these adolescents can be assessed on a case-by-case basis. However, an additional dose of vaccine is not harmful, and can be beneficial because it would likely boost immunity.
Healthy adolescents who have received a dose of quadrivalent meningococcal polysaccharide vaccine in the past (such as Mencevax or Menomune) should receive a dose of conjugate MenACWY vaccine at age 15–19 years. MenACWY vaccine should be given at least 6 months after the dose of quadrivalent meningococcal polysaccharide vaccine.